A team led by Christian Baumgartner of the Institute of Health Care Engineering at Graz University of Technology (TU Graz) ...

The RESOLUTE phase III trial of AstraZeneca’s Fasenra (benralizumab), despite showing numerical improvement, did not achieve statistical significance in the primary endpoint in patients with chronic ...

Regular physical activity reduces the risk of chronic obstructive pulmonary disease (COPD)1 and improves the prognosis in affected patients.2 In contrast, ambient air pollution, is a substantial risk ...

AstraZeneca's Fasenra misses the primary COPD endpoint while Saphnelo's lupus trial shows significant improvements and ...

AstraZeneca ( NASDAQ: AZN) said that the late-stage trial for its medication Fasenra (benralizumab) in patients suffering ...

Dr. Ross Camidge has helped treat thousands of lung cancer patients. Now, in a crazy life twist, Camidge is a lung cancer patient himself.

Topline data were announced from a phase 3 trial evaluating efzofitimod in patients with pulmonary sarcoidosis.

AstraZeneca (AZN) announced on Wednesday that its late-stage trial of Fasenra in patients with chronic obstructive pulmonary ...

Privately-held Areteia Therapeutics has announced positive results from the Phase III EXHALE-4 efficacy and safety study of ...

Dr. Joshua K. Sabari sat down with Terri Conneran at the 2025 World Conference on Lung Cancer for a conversation on the importance of biomarker testing.

Researchers at the University of Calgary studying a lethal lung disease called pulmonary fibrosis have found that neurons ...

Researchers at the University of Calgary studying a lethal lung disease called pulmonary fibrosis have found neurons, which ...